Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

BMS claims beta3 agonists in patent literature

April 5, 1996

ACAT inhibitors claimed by DuPont Merck

April 5, 1996

Pierre Fabre reports hypocholesterolemic organosilanes

April 5, 1996

Vitronectin antagonist from Merck & Co. inhibits bone resorption

April 5, 1996

Cortecs licenses salmon calcitonin to Teva

April 5, 1996

Tsumura Juntendo research into aldose reductase inhibitors

March 15, 1996

AI-401 slated to enter phase II

March 15, 1996

Sankyo reports drugs for diabetes

March 15, 1996

Antidiabetic drugs claimed by Tanabe Seiyaku

March 15, 1996

FDA approves Medtronic's blood processing system

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 11, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.